Privia Health Group, Inc. (PRVA) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $131.13M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 4.66× | Operating cash flow / net income. Period ending 2026-06-30. $131.13M ÷ $28.12M ≈ 4.66× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 131.13M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 28.12M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $131.13M | (m) | (m) | (m) | (m) | $28.12M | (m) | (m) | (m) | 4.66× |
| 2026-03-31 | (m) | (m) | $138.00M | (m) | (m) | (m) | (m) | $21.76M | (m) | (m) | (m) | 6.34× |
| 2025-12-31 | (m) | (m) | $163.40M | (m) | (m) | (m) | (m) | $22.92M | (m) | (m) | (m) | 7.13× |
| 2025-09-30 | (m) | (m) | $110.70M | (m) | (m) | (m) | (m) | $18.17M | (m) | (m) | (m) | 6.09× |
| 2025-06-30 | (m) | (m) | $91.86M | (m) | (m) | (m) | (m) | $14.84M | (m) | (m) | (m) | 6.19× |
| 2025-03-31 | (m) | (m) | $118.36M | (m) | (m) | (m) | (m) | $15.62M | (m) | (m) | (m) | 7.58× |
| 2024-12-31 | (m) | (m) | $109.28M | (m) | (m) | (m) | (m) | $14.38M | (m) | (m) | (m) | 7.60× |
| 2024-09-30 | (m) | (m) | $98.58M | (m) | (m) | (m) | (m) | $12.82M | (m) | (m) | (m) | 7.69× |
| 2024-06-30 | (m) | (m) | $87.89M | (m) | (m) | (m) | (m) | $14.93M | (m) | (m) | (m) | 5.89× |
| 2024-03-31 | (m) | (m) | $61.03M | (m) | (m) | (m) | (m) | $18.74M | (m) | (m) | (m) | 3.26× |
| 2023-12-31 | $80.67M | (m) | $80.78M | $113.00K | (m) | (m) | (m) | $23.08M | (m) | (m) | (m) | 3.50× |
| 2023-09-30 | $45.73M | (m) | $45.84M | $105.00K | (m) | (m) | (m) | $38.02M | (m) | (m) | (m) | 1.21× |
| 2023-06-30 | $39.42M | (m) | $39.52M | $103.00K | (m) | (m) | (m) | $34.00M | (m) | (m) | (m) | 1.16× |
| 2023-03-31 | $39.06M | (m) | $39.13M | $70.00K | (m) | (m) | (m) | $16.25M | (m) | (m) | (m) | 2.41× |
| 2022-12-31 | $47.09M | (m) | $47.20M | $104.00K | (m) | (m) | (m) | $-8.59M | (m) | (m) | (m) | -5.50× |
| 2022-09-30 | $5.48M | (m) | $5.72M | $240.00K | (m) | (m) | (m) | $-38.34M | (m) | (m) | (m) | -0.15× |
| 2022-06-30 | $51.81M | (m) | $52.23M | $421.00K | (m) | (m) | (m) | $-49.08M | (m) | (m) | (m) | -1.06× |
| 2022-03-31 | $51.63M | (m) | $52.21M | $581.00K | (m) | (m) | (m) | $-211.14M | (m) | (m) | (m) | -0.25× |
| 2021-12-31 | $54.51M | (m) | $55.06M | $547.00K | (m) | (m) | (m) | $-188.23M | (m) | (m) | (m) | -0.29× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $38.51M | (m) | $38.89M | $380.00K | (m) | (m) | (m) | $31.24M | (m) | (m) | (m) | 1.24× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $18.65M | (m) | $24.36M | $5.71M | (m) | (m) | (m) | $8.24M | (m) | (m) | (m) | 2.95× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |